RNS Number : 6174D

GlaxoSmithKline PLC

27 April 2017

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Philip Hampton

b)

Position/status

Non-Executive Chairman

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£15.83	2,763.740

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-04-26

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Professor Sir Roy Anderson

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£15.83	454.043

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-04-26

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr Vindi Banga

b)

Position/status

Senior Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£15.83	1,816.172

d)

Aggregated information

A

ggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-04-26

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Vivienne Cox

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£15.83	335.597

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-04-26

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms Lynn Elsenhans

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
$41.13	1,202.913

d)

Aggregated information

A

ggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-04-26

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Jesse Goodman

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

Dr Jesse Goodman was appointed to the Board with effect from 1 January 2016, as previously announced, and in accordance with the share allocation arrangements for Independent Non-Executive Directors, 25% of his fees were retained to be reinvested in notional ADSs at a date to be mutually agreed.

The accumulated balance of the retained fees has now been reinvested as disclosed below.

Going forward, notional ADSs of the Company will be allocated on a quarterly basis.

Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2016 to 31 March 2017.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
$41.13	1,739.846

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-04-26

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms Judy Lewent

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
$41.13	449.364

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-04-26

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr Urs Rohner

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£15.83	628.986

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-04-26

f)

Place of the transaction

n/a

This information is provided by RNS

The company news service from the London Stock Exchange

END DSHQDLFLDZFXBBQ